Myomo corrects Harry Kovelman's 15,844-share sale

The amendment corrects transposed figures for the shares sold and Harry Kovelman's resulting beneficial ownership.

This filing corrects an earlier one, and you can read the original Form 4 if you want to see what changed.

Rhea-AI Filing Summary

MYOMO, Inc. Chief Medical Officer Harry Kovelman sold 15,844 shares of common stock on September 11, 2026, at an average price of $1.2709 per share. The sales occurred in multiple lots at prices ranging from $1.25 to $1.29 per share. His reported direct holdings afterward were 89,889 shares. The amendment corrects a transposition error in the number of shares sold and the resulting beneficial ownership; no Rule 10b5-1 plan is reported.

Insider Trade Summary

Net Seller: 15,844 shares

Net Sell 1 txn

Insider Kovelman Harry

Role Chief Medical Officer

Sold 15,844 shs ($20K)

Type	Security	Shares	Price	Value
Sale	Common Stock F1	15,844	$1.2709	$20K

Holdings After Transaction: Common Stock — 89,889 shares (Direct)

Footnotes (1)

1. F1. Represents average sales price. Transactions were completed in multiple lots at prices ranging from $1.25 to $1.29 per share. Reporting party agrees to provide details of the transactions to the SEC upon request.

Key Figures

Shares sold: 15,844 shares Average sales price: $1.2709 per share Direct holdings after transaction: 89,889 shares +1 more

4 metrics

Shares sold 15,844 shares Harry Kovelman transaction on September 11, 2026

Average sales price $1.2709 per share Harry Kovelman transaction on September 11, 2026

Direct holdings after transaction 89,889 shares Harry Kovelman, after the September 11, 2026 transaction

Sale price range $1.25 to $1.29 per share Prices across multiple lots

Key Terms

average sales price, multiple lots, beneficially owned, transposition error

4 terms

average sales price financial

"Represents average sales price."

multiple lots financial

"Transactions were completed in multiple lots"

beneficially owned financial

"shares beneficially owned following the transaciton"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

transposition error technical

"correct a transposition error on the number of shares sold"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many MYO shares did Harry Kovelman sell, and at what price?

Harry Kovelman, MYOMO, Inc.'s Chief Medical Officer, sold 15,844 shares on September 11, 2026, at an average price of $1.2709 per share. The sales occurred in multiple lots priced from $1.25 to $1.29 per share. His reported direct holdings afterward were 89,889 shares, and no Rule 10b5-1 plan is reported.

Why was MYO's Form 4/A amended?

The amendment corrects a transposition error in the number of shares sold and the resulting beneficial ownership after Harry Kovelman's September 11, 2026 transaction.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/15/2026 - 04:29 PM EDT Accepted by SEC EDGAR 10/15/2026 - 04:28 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kovelman Harry

(Last) (First) (Middle)

C/O MYOMO, INC.

45 BLUE SKY DR., SUITE 101

(Street)

BURLINGTON MASSACHUSETTS 01803

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
MYOMO, INC. [ MYO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)
09/14/2026

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/11/2026		S		15,844	D	$1.2709(1)	89,889	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents average sales price. Transactions were completed in multiple lots at prices ranging from $1.25 to $1.29 per share. Reporting party agrees to provide details of the transactions to the SEC upon request.

Remarks:

This Amendment is being filed to correct a transposition error on the number of shares sold and resulting change in shares beneficially owned following the transaciton on September 11, 2026.

	/s/ David A. Henry, Attorney-in-Fact	10/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)